Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects

European Journal of Pharmaceutical Sciences

Volumn 63, Issue , 2014, Pages 147-153

  Hoch, M ^a   D'Ambrosio, D ^a   Wilbraham, D ^b   Brossard, P ^a   Dingemanse, J ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Heart rate reduction; Pharmacodynamics; Pharmacokinetics; Ponesimod; Safety and tolerability

Indexed keywords

PLACEBO; PONESIMOD; SALBUTAMOL; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FORCED EXPIRATORY VOLUME; HEART FUNCTION; HEART RATE; HUMAN; HUMAN EXPERIMENT; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE SCLEROSIS; NIGHT SWEAT; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FUNCTION; THORAX PAIN; VISUAL IMPAIRMENT; ADOLESCENT; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, LYSOSPHINGOLIPID; THIAZOLES; YOUNG ADULT;

EID: 84907353435     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.07.005     Document Type: Article

References (25)

1. J.J. Aarthi, M.A. Darendeliler, and P.N. Pushparaj Dissecting the role of the S1P/S1PR axis in health and disease J. Dent. Res. 90 2011 841 854
2. M.H. Bolli, S. Abele, C. Binkert, R. Bravo, S. Buchmann, D. Bur, J. Gatfield, P. Hess, C. Kohl, C. Mangold, B. Mathys, K. Menyhart, C. Müller, O. Nayler, M. Scherz, G. Schmidt, V. Sippel, B. Steiner, D. Strasser, A. Treiber, and T. Weller 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists J. Med. Chem. 53 2010 4198 4211
3. P. Brossard, D. D'Ambrosio, I. Murat, and J. Dingemanse Effects of three different up-titration regimens of ponesimod, a selective S1P1 receptor agonist, on heart rate Clin. Pharmacol. Ther. 91 Suppl. 1 2012 S93
4. P. Brossard, H. Derendorf, J. Xu, H. Maatouk, A. Halabi, and J. Dingemanse Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study Br. J. Clin. Pharmacol. 76 2013 888 896
5. P. Brossard, M. Scherz, A. Halabi, H. Maatouk, A. Krause, and J. Dingemanse [Epub ahead of print]. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration J. Clin. Pharmacol. 2014 doi: http://dx.doi.org/10.1002/ jcph.244
6. J. Chun International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature Pharmacol. Rev. 54 2002 265 269 (Pubitemid 34575716)
7. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, X. Montalban, J. Pelletier, R. Capra, P. Gallo, G. Izquierdo, K. Tiel-Wilck, A. de Vera, J. Jin, T. Stites, S. Wu, S. Aradhye, L. Kappos TRANSFORMS Study Group Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N. Engl. J. Med. 362 2010 402 415
8. M. Gibaldi, and D. Perrier Pharmacokinetics 1982 Dekker, New York
9. Gilenya Prescribing Information. Novartis. May 2012.
10. A. Horga, J. Castilló, and X. Montalban Fingolimod for relapsing multiple sclerosis: an update Expert Opin. Pharmacother. 11 2010 1183 1196
11. I. Ishii, N. Fukushima, X. Ye, and J. Chun Lysophospholipid receptors: signaling and biology Annu. Rev. Biochem. 73 2004 321 354 (Pubitemid 39050372)
12. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, P. Calabresi, K. Selmaj, C. Agoropoulou, M. Leyk, L. Zhang-Auberson, P. Burtin FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N. Engl. J. Med. 362 2010 387 401
13. A. Khasnis, R.M. Gokula Romberg's test J. Postgrad. Med. 49 2003 169 172
14. J.M. Kovarik, R. Schmouder, D. Barilla, G.J. Riviere, Y. Wang, and T. Hunt Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects J. Clin. Pharmacol. 44 2004 532 537 (Pubitemid 38509722)
15. J.W. Lindsey, K. Haden-Pinneri, N.B. Memon, and L.M. Buja Sudden unexpected death on fingolimod Mult. Scler. 18 2012 1507 1508
16. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrin, G. Viegi, J. Wanger ATS, ERS Task Force Standardisation of spirometry Eur. Respir. J. 26 2005 319 338 (Pubitemid 41079078)
17. T. Olsson, A. Boster, Ó. Fernández, M.S. Freedman, C. Pozzilli, D. Bach, O. Berkani, M.S. Mueller, T. Sidorenko, and M. Melanson Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial Mult. Scler. J. 18 4 suppl 2012 49 (152)
18. L. Piali, S. Froidevaux, P. Hess, O. Nayler, M.H. Bolli, E. Schlosser, C. Kohl, B. Steiner, and M. Clozel The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation J. Pharmacol. Exp. Ther. 337 2011 547 556
19. M. Reyes, P. Brossard, D. Chassard, M. Hoch, and J. Dingemanse Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive Eur. J. Clin. Pharmacol. 70 2014 287 293
20. M.G. Sanna, J. Liao, E. Jo, C. Alfonso, M.Y. Ahn, M.S. Peterson, B. Webb, S. Lefebvre, J. Chun, N. Gray, and H. Rosen Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate J. Biol. Chem. 279 2004 13839 13848 (Pubitemid 38468916)
21. R. Schmouder, D. Serra, Y. Wang, J.M. Kovarik, J. DiMarco, T.L. Hunt, and M.C. Bastien FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects J. Clin. Pharmacol. 46 2006 895 904 (Pubitemid 44050826)
22. R. Schmouder, S. Hariry, and O.J. David Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers Eur. J. Clin. Pharmacol. 68 2012 355 362
23. J.B. Schwartz The influence of sex on pharmacokinetics Clin. Pharmacokinet. 42 2003 107 121 (Pubitemid 36188552)
24. S. Thangada, K.M. Khanna, V.A. Blaho, M.L. Oo, D.S. Im, C. Guo, L. Lefrancois, and T. Hla Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics J. Exp. Med. 207 2010 1475 1483
25. J. Wise Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug BMJ 344 2012 e1360